EricRubensteinMD

Medical Director of Hematology and Oncology

Dr. Rubenstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

PubMed

11 citations
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias
Tara L. Lin, Laura F. Newell, Robert K. Stuart, Laura C. Michaelis, Eric Rubenstein, Helen S. Pentikis, Timothy Callahan, Donna Alvarez, Barry D. Liboiron, Lawrence D....> ;Cancer Chemotherapy and Pharmacology. 2019 May 16
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy ...
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausova J, Garcia-Alfonso P, Yamazaki ...> ;Lancet Oncol. 2015 May

Journal Articles

Pregnancy Complications and Maternal Birth Outcomes in Women with Intellectual and Developmental Disabilities in Wisconsin Medicaid
Eric Rubenstein, MD, PLoS One

Lectures

Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb™ Adsorber and PerLife™ Organ Perfusion System, Respectively, at the European Society of Organ Transplantation CongressAugust 30th, 2021
CytoSorbents Awarded $1.5 Million Sequential Phase II SBIR Contract to Advance the Treatment of Severe Hyperkalemia in Traumatic InjuryMay 11th, 2021
Women with Disabilities at Risk for Adverse Pregnancy Outcomes, Study FindsDecember 1st, 2020
Join now to see all